Restricted accessResearch articleFirst published online 1988-10
Molecular Profile,Tissue Distribution and Prognostic Evaluation of a Human Melanoma-Carcinoma Antigen Recognized by the Murine Monoclonal Antibody B1.1
Using the murine monoclonal antibody (MoAb) B1.1 we have analyzed the immunochemical profile and the tissue distribution of a human melanoma associated antigen (MAA) carrying an epitope shared by the 180 kd CEA. Results of this study have demonstrated that the epitope expressed by the MAA is carried by a distinct set of molecules of 110-140 kd. Similarly to the 180 kd CEA molecules synthesized by carcinomas, the expression of the melanoma associated CEA like components (MA-CEA) is upregulated by IFN-α. The tissue distribution of MA-CEA is not restricted to malignant primary and metastatic melanocytic lesions but is found also at low levels in 64% of benign nevi. No circulating CEA was found in patients bearing widespread metastatic disease of MA-CEA positive lesions.
Preliminary clinical evaluation of stage I melanoma patients bearing MoAb Bl. l positive lesions has not shown a significative prognostic association of this phenotypic marker with clinical course of the disease.
NataliP.G., AguzziA., VegliaF.. The impact of monoclonal antibodies on the study of human malignant melanoma.J Cutaneous Path1983; 10: 514–23.
2.
NataliP.G., GiacominiP., RussoC., SteinbachG., FenoglioC., FerroneS.Antigenic profile of human melanoma cells. Analysis with monoclonal antibodies to histocompatibility antigens and to melanoma-associated antigens.J Cutaneous Path1983; 10: 225–37.
3.
HagemanP.H., VennegorC., Van der ValkM., LandergentJ., JonkerA., Van der MispelL.Reaction of monoclonal antibodies against human melanoma with different tissues and cell lines. In: Peter H, ed. Protides of the biological fluids.New York Perganon Press1982; 29: 889–92.
4.
ImanA., MitchellM.S., ModlinR.L., TaylorC.R., KenyfP.A., Kan-MitchellJ.Human monoclonal antibodies that distinguish cutaneous malignant melanomas from benign nevi in fixed tissue sections.J Inv Dermat1986; 86: 145–8.
5.
LehmannJ.M., HolzmannB., BreitbartE., SchmiegelowP., RithmullerG., JohnsonJ.P.Discrimination between benign and malignant cells of melanocytic lineage by two novel, a glycoprotein with a molecular weight of 113.000 and a protein with a molecular weight of 76.000.Cancer Res1987; 47: 841–5.
6.
SiccardiA.G., BuraggiG.L., CallegaroL.. Multicenter study of immunoscintigraphy with radiolabelled monoclonal antibodies in patients with melanoma.Cancer Res1986; 46: 4817–22.
7.
ColcherD., Horand HandP., NutiM., SchlomJ.Differential binding to human mammary and nonmammary tumors of monoclonal antibodies reactive with carcinoembryonic antigen.Cancer Invest1983; 1: 127–38.
8.
FisherP.B., PrignoliD.R., HermoH.Effects of combined treatment with interferon and meze-rein on melanogenesis and growth in human melanoma cells.J Inter Res1985; 5: 11–22.
9.
ColcherD., Horand HandP., NutiM., SchlomJ.A spectrum of monoclonal antibodies with human mammary tumor cells.Proc Natl Acad Sci USA1981; 78: 3199–203.
10.
AccollaR.S., CarrellS., MachJ.P.Monoclonal antibodies specific for carcinoembryonic antigen and produced by two hybrid cell lines.Proc Natl Acad Sci USA1980; 77: 563–6.
11.
ParhamP., BarnastableC.J., BodmerW.F.Use of monoclonal antibody in structural studies of HLA-A,B,C antigens.J Immunology1979; 23: 342–9.
12.
LaemmliU.K.Cleavage of structural proteins during the assembly of the head of bacteriophage T4.Nature1970; 227–80.
13.
BonnerW.M., LaskeyR.A.A film detection method for tritium labelled proteins and nucleic acids in polyacrylamide gels.Europ J Biochem1974; 6: 83–8.
14.
SugarbakerE.V., Mc BrideC.M.Survival and regional disease control after isolation perfusion for invasive stage I melanoma of the extremities.Cancer1976; 37: 188–98.
15.
NataliP.G., BigottiA., NicotraM.R., VioraM., ManfrediD., FerroneS.Distribution of human class I (HLA-A,B,C) histocompatibility antigens in normal and malignant tissues of nonlymphoid origin.Cancer Res1984; 44: 4679–84.
16.
LeeE., DesuM.A computer program for comparing K samplex with right-censored data.Computer Programs in Biomedicine1972; 2: 315–21.
17.
GreinerJ.W., TobiM., FisherP.B., LangerJ.A., PestkaS.Differential responsiveness of cloned mammary carcinoma cell population to the human recombinant interferon enhancement of tumor antigen expression.Int J Cancer1985; 36: 159–66.
18.
KoprowskiH., SteplewskiZ., HerlynD., HerlynM.Study of antibodies against human melanoma produced by somatic cell hybridis.Proc Natl Acad Sci USA1978; 75: 3405–9.
19.
YehM.Y., HellstromJ., BrownJ.P., WarnerG.A., HansenJ.A., HellstromK.E.Cell surface antigens on human melanoma identified by monoclonal antibody.Proc Natl Acad Sci USA1979; 76: 2927–31.
20.
ImaiK., WilsonB.S., BigottiA., NataliP.G., FerroneS.A 94.000 dalton glycoprotein expressed by human melanoma and carcinoma cells.J Natl Cancer Inst1982; 68: 761–9.
21.
CheeD.O., YonemotoR.H., LeongS.P.L.. Mouse monoclonal antibody to a melanoma-carcinoma associated antigen synthesized by a human melanoma cell line propagated in serum-free medium.Cancer Res1982; 42: 3142–7.
22.
LiaoS.K., KwongP.C., ClarkeB.J.. Monoclonal antibodies recognizing human melanoma-carcinoma cross reacting oncofetal antigen epi-topically associated with carcinoembryonic antigen.J Natl Cancer Inst1985; 74: 1047–57.
23.
AttallahA.M., NeedyC.F., NoguchiP.D., ElisbergB.L.Enhancememt of carcinoembryonic antigen expression by interferon.Int J Cancer1979; 24: 49–52.
24.
MiescherG., Von AlbertiniA.Histologie de 100 cas de nevi pigmentaires d'après les méthodes de Masson.Bull Soc Fr Dermatol Symph1935; 42: 1265–74.
25.
GiacominiP., VegliaF., Cordiali FeiP., RehleT., NataliP.G., FerroneS.Levels of a membrane-bound high molecular weight melanoma associated antigen and a cytoplasmic melanoma-associated antigen in surgically removed tissues and in sera from patients with melanoma.Cancer Res1984; 44: 1281–7.
26.
BrownJ.P., WoodburyR.D., HartC.E., HellstromI., HellstromK.E.Quantitative analysis of melanoma associated antigen p97 in normal and neoplastic tissues.Proc Natl Acad Sci1981; 78: 539–43.
27.
MorganAc, CraneM.H., RossenR.D.Measurement of a monoclonal antibody-defined, melanoma associated antigen in human sera: correlation of circulating antigen levels with tumor burden.J Natl Cancer Inst1984; 72: 243–9.
28.
RuiterD.J., Van DuinenS.G., TsujisakiM., FerroneS.Class II HLA antigen in benign and malignant lesions of melanocytic origin. In: SolheimB.G., MolherE., FerroneS., eds. HLA class II antigens. A comprehensive review of structure and function.Springer-Verlag1986; 429–41.
29.
BrockerR.B., SuterL., BrugeenJ., RuiterD.J., MacherE., SorgC.Phenotypic dynamics of tumor progression in human malignant melanoma.Int J Cancer1985; 36: 29–35.
30.
NataliP.G., RobertsJ.T., Di FilippoF.. Im-munohistochemical detection of antigen in human primary and metastatic melanomas by the monoclonal antibody 140.240 and its possible prognostic significance.Cancer1987; 59: 55–63.
